Application of High Tumorigenicity Prostate Cancer Sub-clone Cell Line in Antigene Therapy

【Objective】 To testify the value of high tumorigenicity prostate cancer sub-clone cell line LNCap1-luc in anticancer drugs research through building subcutaneous tumor model,and applicating in antigene therapy.【Methods】 Twenty-four nude mice were inoculated with LNCap1-luc cell line,and were randomized into 3 groups:TFO treatment group,SCO treatment group,NS control group.Each group underwent intra-tumor injection at the same dose of 15 mg/Kg for 6 weeks.During treatment,mouse tumor size and body weight were monitored.After 6 weeks treatment,AR mRNA was detected by qRT-PCR.AR,PSA,and Ki-67 were tested by immunohistology.Cellular apoptosis was assayed by TUNEL.【Results】 The tumor inhibition rate of TFO group was 63.16%.The relative percentage of AR mRNA in TFO group was(39.16 ± 6.67)%;the rate of positive nuclei of Ki-67 in TFO group was(25.43 ± 2.01)%;The AI(apoptosis index) of TFO group was(35.76 ± 2.35)%;compared with the NS group,there was statistical difference(P 0.05).The expression level of AR and PSA in TFO group was lower than NS group.【Conclusion】 TFO can effectively inhibit tumor growth of LNCap1-luc prostate cancer xenograft.LNCap1-luc cell line provides a new cell model for anticancer drugs therapy of prostate cancer,and has a promising future for application.